A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, Or Peduncular High-Grade Glioma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide
- Indications Glioma
- Focus Therapeutic Use
- Acronyms HERBY
- Sponsors Roche
- 06 Jun 2017 Results of an integrated analysis assessing the effects of bevacizumab on growth/development in pediatric/adolescent patients (n=403), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 27 Apr 2016 An additional young patient cohort has been added who will receive bevacizumab and temozolomide without radiation therapy. Treatment arms increased from 2 to 3.
- 11 May 2015 Planned End Date changed from 1 May 2020 to 1 Mar 2020, as reported by ClinicalTrials.gov.